Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus Clinical Trial

Official title:

A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride Alone

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02089126
• Other study ID #: LG-GGCL001
• Status: Not yet recruiting
• Phase: Phase 3
• First received: March 13, 2014
• Last updated: March 14, 2014
• Start date: June 2014

Study information

• Verified date: March 2014
• Source: LG Life Sciences
• Contact: Jong Hee Jin
• Phone: 82-2-6924-3122
• Email: jonghee[@]lgls.com
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study objective is to demonstrate the superiority and safety of the combination therapy (as a fix-dose combination) with Gemigliptin and Glimepiride, compared to the Glimepiride monotherapy in patients with type 2 diabetes.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 230
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Patients with type 2 diabetes

2. Adults who are at least 19 years old

3. Patients who have taken Glimepiride at a stable dose (=4mg/day) for 8 weeks or more before Visit 1 (screening) as monotherapy or Patients who have taken Glimepiride at a stable dose (=4mg/day) and Metformin for 8 weeks or more before Visit 1 (screening) as combination therapy

4. Patients who satisfy the following HbA1c (%) criteria: 7 = HbA1c = 11

5. Patients who have been provided an explanation about the objective, method, effects, etc. of the clinical trial and whose informed consent form has been signed by himself/herself or his/her representative

6. Patients who fall under one of the following 3 cases

1. Patients who are surgically sterile

2. Post-menopausal females who are above 45 years of age and 2 years after the last menstruation

3. Fertile premenopausal female patients or male patients without having a surgical sterilization, who have agreed to use at least two contraception methods (one of the barrier methods must be included) for up to 14 days after the administration of the last investigational product to avoid pregnancy.

Exclusion Criteria:

1. Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma

2. Patients with gestational diabetes or secondary diabetes

3. Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring treatment

4. Patients with thyroid gland dysfunction and TSH that is out of normal range

5. Patients with pituitary insufficiency or adrenal insufficiency

6. Patients with hereditary problems, such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption

7. Female patients who are pregnant or breastfeeding

8. Patients whose BMI exceeds 40 kg/m2

9. Patients whose creatinine clearance is below 30mL/min/1.73m2

10. Patients whose bilirubin level exceeds 1.5 times the upper limit of the normal range and whose ALT/AST level exceeds 2.5 times the upper limit of the normal range

11. Patients who are continuously taking the following drugs for 2 weeks or more at Visit 1 (screening), or need to take them continuously and repeatedly

• cyclosporin, sirolimus, tacrolimus, nicotinic acid (=1500mg/day), isotretinoin

• Strong CYP3A4 inducers: rifampicin (rifampin), phenytoin, carbamazepine, rifabutin, phenobarbital

• warfarin, dicoumarin, digoxin

• systemic glucocorticoids

12. Patients who have taken anti-obesity drugs or had a surgery related to obesity within 12 weeks before Visit 1 (screening)

13. Patients who have received insulin and GLP-1 analogue treatment within 8 weeks prior to Visit 1 (screening)

14. Patients who have received a treatment due to malignant tumor within 5years before Visit 1 (screening) However, patients whose basal cell or squamous cell skin cancer or in situ cervical cancer has been treated can be enrolled.

15. Patients with a history of myocardial infarction, unstable angina and coronary artery bypass surgery within 6 months prior to Visit 1 (screening)

16. Patients with a history of alcohol or drug addiction within 1 year prior to Visit 1 (screening)

17. Patients who have a medical history of hypersensitivity to the same class as Gemigliptin or dipeptidyl peptidase 4 (DPP 4) inhibitor drugs

18. Patients with a history of hypersensitivity to the drugs belonging to the same class as Glimepiride or sulfonylureas and sulfonamide

19. Patients who have participated in another clinical trial within 3 months prior to Visit 1 (screening)

20. Patients deemed unsuitable for this trial based on the judgment of the investigator

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Gemigliptin/Glimepiride combination

Locations

Country	Name	City	State
Korea, Republic of	The Catholic University of Korea Seoul St. Mary's Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
LG Life Sciences

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1c Changes		Week 0, Week 24	No